Swan EndoSurgical
Swan EndoSurgical is a Boston-based, pre-commercial medical device startup developing a flexible endoluminal robotic platform for minimally invasive gastrointestinal procedures, co-founded by Olympus and Revival Healthcare Capital to serve hospitals performing GI endoscopy and colorectal cancer treatment.
- Company typePrivate
- Founded2025
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Swan EndoSurgical does
Swan EndoSurgical is a Boston-based, pre-commercial medical device startup founded in July 2025 that is developing a flexible endoluminal robotic platform for minimally invasive gastrointestinal procedures. The company's core technology is a robotic system equipped with flexible robotic arms designed for GI tract interventions, built on top of Olympus Corporation's visualization and endoscopy technology stack. The platform is intended to enable and democratize technically demanding endoscopic procedures such as endoscopic submucosal dissection (ESD), which currently require 200-300 procedures to achieve clinical proficiency, with the broader clinical aim of broadening access to minimally invasive GI care, particularly for colorectal cancer.
Swan EndoSurgical firmographics
Firmographics- Name
- Swan EndoSurgical
- Legal name
- Swan EndoSurgical
- Website
- https://swanendosurgical.com
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Swan EndoSurgical is a Boston-based, pre-commercial medical device startup developing a flexible endoluminal robotic platform for minimally invasive gastrointestinal procedures, co-founded by Olympus and Revival Healthcare Capital to serve hospitals performing GI endoscopy and colorectal cancer treatment.
- Ownership category
- akta.pro rank
Swan EndoSurgical industry classification
Industry- Product category
- Surgical Robotics
- NAICS
- Surgical Appliance and Supplies Manufacturing (339113), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Surgical Robotics & Computer-Assisted Surgery Platforms (HLAHADAF)
- akta.pro secondary industries
- Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation) (HLAHADAB), Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN)
Keywords
Where Swan EndoSurgical is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Swan EndoSurgical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
Revenue model
- Medical Device Sales: Swan EndoSurgical develops and commercializes robotic systems for minimally invasive gastrointestinal procedures. As a medical device company, revenue is generated through the sale of surgical robotic systems to healthcare providers and hospitals.
Swan EndoSurgical product offering
Product offeringCore offering
Swan EndoSurgical develops endoluminal surgical robotic systems for minimally invasive gastrointestinal (GI) procedures. The company's flexible endoluminal robotic platform uses miniaturized robotic arms designed for GI tract interventions such as endoscopic submucosal dissection (ESD), with the goal of democratizing technically demanding endoscopic procedures that currently require 200–300 cases to achieve proficiency.
Product overview
Swan EndoSurgical is developing a unified robotic platform for minimally invasive gastrointestinal procedures. The company is building an endoscopic robot and a flexible endoluminal robotic platform with flexible robotic arms for GI tract interventions, both leveraging core visualization and endoscopy technology supplied by Olympus. The platform aims to democratize technically demanding endoscopic procedures such as endoscopic submucosal dissection (ESD), which currently requires 200-300 procedures to achieve proficiency.
Differentiator
Problem solved
Functional benefit
Products and services
- Flexible Endoluminal Robotic Platform (Endoscopic Robot for Gastrointestinal Treatments)
Quantifiable outcome
- Addresses colorectal cancer, the second leading cause of cancer with nearly 900,000 deaths annually
- +1 more outcomes
Companies that use Swan EndoSurgical
Customer profileSegments1 record
Ideal customer profiles1 record
Swan EndoSurgical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Swan EndoSurgical partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Olympus CorporationcoreOlympus co-founded Swan EndoSurgical to develop robotic systems for minimally invasive gastrointestinal procedures. Olympus supplies core visualization and endoscopy technology while retaining an option to acquire the startup if pre-set value milestones are achieved. The partnership aims to address the growing global incidence of colorectal cancer through robotics.
Scale indicators2 records
Recent moves9 records
Expansion highlights5 records
Swan EndoSurgical competitors and assessment
Company assessmentDirect peers
- Intuitive Surgical: Intuitive Surgical is the dominant surgical robotics company with the da Vinci platform and the emerging Ion endoluminal system for lung biopsy. It is the most direct comparator to Swan because it is racing to bring endoluminal robotics into clinical use and owns the same hospital/customer base in MIS and flexible endoscopy.
- Medtronic: Medtronic's Hugo robotic-assisted surgery system is a direct competitor in the MIS robotic surgery category and Medtronic has deep GI/AI Sculptor systems ties. It competes for the same hospital capital dollars and GI surgical indications Swan targets.
- EndoQuest Robotics: EndoQuest Robotics is developing a flexible endoluminal robotic system (the Endomaster/ELS) for upper and lower GI procedures including ESD. It is the closest pure-play competitor to Swan, targeting the same flexible endoluminal GI use cases and the same pool of academic and community GI surgeons.
- Asensus Surgical: Asensus Surgical (formerly TransEnterix) develops the Senhance and subsequent platforms for laparoscopic and potentially flexible endoscopic surgery. It is a direct comparator as a publicly traded pure-play surgical robotics company pursuing next-generation digital laparoscopy and adjacent indications.
Broad incumbents
- Stryker: Stryker's Mako robotic system is the dominant orthopedic surgical robotics platform and the former employer of Swan's CEO Erik Todd. It is a broad incumbent in surgical robotics, with a different anatomical focus but the same commercialization playbook Swan must execute in MIS robotics.
- Johnson & Johnson MedTech (Ethicon / MONARCH): J&J MedTech operates the MONARCH robotic bronchoscopy platform (an endoluminal competitor in lung) and previously invested in flexible surgical robotics via Verb. It is a broad incumbent with the balance sheet and GI/Ethicon salesforce to enter Swan's market at scale.
- Olympus Corporation: Olympus is the dominant GI endoscopy OEM (gastroscopes, colonoscopes, processors) and a co-founder/strategic investor in Swan. As the parent-tech supplier and potential acquirer, Olympus is also the broader incumbent whose installed visualization base Swan depends on and that could itself internalize the robotics layer.
Emerging players
- Noah Medical: Noah Medical commercializes the Galaxy System for robotic bronchoscopy, competing in endoluminal robotics. While lung-focused, its engineering approach to flexible articulation in tortuous anatomy makes it a relevant emerging peer for Swan's endoluminal platform development.
- Vicarious Surgical: Vicarious Surgical is developing a combined virtual-reality, single-port robotic surgery system targeting abdominal procedures. It is an emerging peer in next-generation surgical robotics pursuing minimally invasive approaches analogous to Swan's flexible-platform thesis.
- Virtual Incision: Virtual Incision is developing the MIRA miniature surgical robotic platform for minimally invasive abdominal surgery. While intra-corporeal rather than intraluminal, it is a relevant emerging peer in the broader robotic MIS race for limited-port procedures.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Swan EndoSurgical social profiles
Digital presenceSwan EndoSurgical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Swan EndoSurgical leadership team
Management profileNumber of profiles
Profiles3 records
Swan EndoSurgical funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Swan EndoSurgical M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Swan EndoSurgical
What does Swan EndoSurgical do?
Swan EndoSurgical develops endoluminal surgical robotic systems for minimally invasive gastrointestinal (GI) procedures. The company's flexible endoluminal robotic platform uses miniaturized robotic arms designed for GI tract interventions such as endoscopic submucosal dissection (ESD), with the goal of democratizing technically demanding endoscopic procedures that currently require 200–300 cases to achieve proficiency.
Is Swan EndoSurgical a public or private company?
Swan EndoSurgical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Swan EndoSurgical founded?
Swan EndoSurgical was founded in 2025. It employs 11 to 50 people.
Where is Swan EndoSurgical based?
Swan EndoSurgical is headquartered in Boston, United States, in the North America region.
How does Swan EndoSurgical make money?
One revenue line is on record: medical Device Sales.
Who are Swan EndoSurgical's main competitors?
Direct peers on record are Intuitive Surgical, Medtronic, EndoQuest Robotics and Asensus Surgical. Broad incumbents are Stryker, Johnson & Johnson MedTech (Ethicon / MONARCH) and Olympus Corporation. Emerging players are Noah Medical, Vicarious Surgical and Virtual Incision.
Does Swan EndoSurgical have an API?
No public API is recorded for Swan EndoSurgical.
What industry is Swan EndoSurgical in?
Swan EndoSurgical's product category is Surgical Robotics. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHADAB, Endoscopy Systems & Accessories (Scopes, Cameras, Light Sources, Insufflation). Its NAICS code is 339113 and its SIC code is 3841.